Older glucocentric drugs are still commonly used by patients but have limited evidence for CV outcomes; hence, it is pivotal to augment T2DM regimens with GLP-1R agonists and SGLT2 inhibitors, especially in patients at increased CV risk. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.